Filing Flows › Generate Biomedicines (GENB) › Q2 2026 › vs Q2 2025
Generate Biomedicines (GENB) Q2 2026 vs Q2 2025 (year over year)
Generate Biomedicines's revenue fell $3.8M (-38%) from $10.1M in Q2 2025 to $6.3M in Q2 2026.
Generate Biomedicines, Q2 2026: revenue $6.3M (-38% year over year), net loss $67.3M, operating cash flow −$57.9M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $6.3M | $10.1M | −$3.8M | -38% |
| Other income, net | $4.4M | $3.5M | $960K | +28% |
| Net loss | $67.3M | $56.7M | $10.5M | +19% |
| Costs & expenses | $78.0M | $70.3M | $7.7M | +11% |
| Operating costs | $77.9M | $70.3M | $7.6M | +11% |
| Income tax | $53K | $44K | $9K | +20% |
| Research & development | $64.3M | $59.7M | $4.6M | +8% |
| General & admin | $13.6M | $10.5M | $3.1M | +29% |
| Operating cash sources | $69.4M | $57.5M | $11.8M | +21% |
| Depreciation & amortization | $3.2M | $3.3M | −$100K | -3% |
| Share-based compensation | $8.2M | $5.5M | $2.8M | +50% |
| Cash used in operations | $57.9M | $48.8M | $9.2M | +19% |
| Net loss absorbed | $67.3M | $56.7M | $10.5M | +19% |
| Working capital & other | $2.1M | $798K | $1.3M | +167% |
Questions
How much did Generate Biomedicines's revenue grow year over year in Q2 2026?
Generate Biomedicines's revenue fell $3.8M (-38%) from $10.1M in Q2 2025 to $6.3M in Q2 2026.